GSA Capital Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$292K	Sell	185,061 -145,920	-44%	-$246K	0.02%	1266
2025 Q4	$553K	Sell	330,981 -339,875	-51%	-$588K	0.05%	740
2025 Q3	$1.13M	Sell	670,856 -226,755	-25%	-$268K	0.09%	322
2025 Q2	$814K	Sell	897,611 -39,281	-4%	-$23.3K	0.06%	589
2025 Q1	$423K	Buy	936,892 +528,055	+129%	+$310K	0.04%	911
2024 Q4	$205K	Buy	408,837 +315,805	+339%	+$232K	0.02%	1403
2024 Q3	$84K	Buy	+93,032	New	+$86.2K	0.01%	1503
2023 Q3	–	Sell	-13,196	Closed	-$19K	–	1724
2023 Q2	$19K	Buy	+13,196	New	+$18.2K	﹤0.01%	1444
2022 Q4	–	Sell	-48,628	Closed	-$55K	–	1694
2022 Q3	$55K	Sell	48,628 -69,680	-59%	-$102K	0.01%	1414
2022 Q2	$187K	Buy	118,308 +45,802	+63%	+$60.4K	0.03%	1088
2022 Q1	$112K	Buy	+72,506	New	+$113K	0.02%	1275
2021 Q2	–	Sell	-80,000	Closed	-$188K	–	1475
2021 Q1	$188K	Buy	+80,000	New	+$192K	0.03%	925
2020 Q3	–	Sell	-15,191	Closed	-$13K	–	1323
2020 Q2	$13K	Buy	+15,191	New	+$13.4K	0.01%	566
2018 Q1	–	Sell	-190,671	Closed	-$359K	–	1725
2017 Q4	$359K	Sell	190,671 -9,144	-5%	-$20K	0.02%	1122
2017 Q3	$496K	Buy	199,815 +110,661	+124%	+$274K	0.03%	972
2017 Q2	$246K	Buy	+89,154	New	+$249K	0.02%	1401

Other funds holding LCTX